Medtronic plc
NYSE:MDTMedical - Devices
+$0.75 today
- Market cap
- $128.84B
- Beta
- 0.60
- P/E (TTM)
- 21.1
- EPS (TTM)
- $3.74
- Dividend yield
- 3.60%
Volume 6.47M
Average 11.36M
MDT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Medtronic plcNYSE: MDT
Stock-Based Compensation · Q1 FY2027 · quarter ended Jul 2026
Stock-based compensation growth accelerates
Q1 FY2027 stock-based compensation of $125M rose 45.3% year over year, ahead of the +14.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 31.6% from the prior quarter. Over 3 fiscal years it compounded at +8.8% a year.
Context
- Stock-based compensation amounted to 1.3% of revenue in FY2026, unchanged from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +45.3% holds above the trailing-twelve-month pace of +14.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2026
- 457M USD
- Year-over-year change
- +6.5%
- 4-year CAGR
- +6.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2026 | 2026-04-24 | 457M | +6.5% |
| FY2025 | 2025-04-25 | 429M | +9.2% |
| FY2024 | 2024-04-26 | 393M | +10.7% |
| FY2023 | 2023-04-28 | 355M | -1.1% |
| FY2022 | 2022-04-29 | 359M | — |
Stock-Based Compensation vs competitors
How MDT compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.8% is the 3rd highest of 9, against a peer median of +7.7%.
- Stock-based compensation amounts to 1.3% of revenue for MDT, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $496M USD | +14.8% | +8.8% | 1.3% | |
| LTM Jun 2026 | $251M USD | +9.6% | +13.1% | 1.0% | |
| LTM Jun 2026 | $168M USD | -1.5% | +7.6% | 2.6% | |
| LTM Jun 2026 | $166M USD | +5.7% | +10.8% | 0.8% | |
| LTM Jun 2026 | €112M EUR | -17.6% | — | 0.6% | |
| LTM Jun 2026 | $98.2M USD | +13.7% | -4.9% | 1.2% | |
| LTM Jun 2026 | $59.5M USD | +16.5% | — | 4.0% | |
| LTM Sep 2026 | $49.04M USD | +44.9% | -6.8% | 3.3% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $4.48M USD | -15.1% | +38.4% | 241.9% |
| Peer median (excluding MDT) | — | +7.7% | +9.2% | 1.9% | |
Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Apr 2026 |
|---|---|---|---|---|---|
| Net Income | 5.06B | 3.78B | 3.68B | 4.69B | 4.84B |
| Depreciation & Amortization | 2.71B | 2.7B | 2.65B | 2.86B | 2.96B |
| Deferred Income Tax | (604M) | (226M) | (508M) | (316M) | 51M |
| Stock-Based Compensation | 359M | 355M | 393M | 429M | 457M |
| Change in Working Capital | (889M) | (967M) | (484M) | (1.05B) | (1.42B) |
| Accounts Receivables | (477M) | (576M) | (391M) | (433M) | (200M) |
| Inventory | (560M) | (939M) | (139M) | (292M) | (404M) |
| Accounts Payables | 213M | 696M | 391M | 209M | 46M |
| Other Working Capital | (65M) | (148M) | (345M) | (538M) | (865M) |
| Other Non-Cash Items | 711M | 396M | 1.06B | 433M | 450M |
| Operating Cash Flow | 7.35B | 6.04B | 6.79B | 7.04B | 7.33B |
| Capital Expenditures | (1.37B) | (1.46B) | (1.59B) | (1.86B) | (1.9B) |
| Acquisitions (Net) | (91M) | (1.87B) | (211M) | (98M) | (406M) |
| Purchases of Investments | (9.88B) | (7.51B) | (7.75B) | (8.23B) | (8.73B) |
| Sales of Investments | 9.69B | 7.34B | 7.44B | 8.5B | 8.11B |
| Other Investing Activities | (10M) | 4M | (261M) | (249M) | (4M) |
| Investing Cash Flow | (1.66B) | (3.49B) | (2.37B) | (1.94B) | (2.93B) |
| Debt Repayment | (1M) | (598M) | 1.07B | 2.14B | (1.17B) |
| Common Stock Issued | 429M | 308M | 284M | 508M | 516M |
| Common Stock Repurchased | (2.54B) | (645M) | (2.14B) | (3.24B) | (1.04B) |
| Dividends Paid | (3.38B) | (3.62B) | (3.67B) | (3.59B) | (3.64B) |
| Other Financing Activities | 163M | (101M) | (3M) | (184M) | 582M |
| Financing Cash Flow | (5.34B) | (4.96B) | (4.45B) | (4.36B) | (4.75B) |
| Effect of Forex Changes | (230M) | 243M | (230M) | 188M | 85M |
| Net Change in Cash | 121M | (2.17B) | (259M) | 934M | (269M) |
| Free Cash Flow | 5.98B | 4.58B | 5.2B | 5.19B | 5.43B |
Medtronic plc
NYSE:MDT
Intrinsic Alpha fair value
Locked
Current Price
$100.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.